Drugs / WM-S1-030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04801095 | Jul 2021 → Aug 2025 | cholangiocarcinoma, colorectal cancer, head and neck cancer, lung cancer +2 | Wellmarker Bio | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WM-S1-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04801095 ↗ |
| Route | Oral | “Part 1 will investigate oral administration of WM-S1-030 as monotherapy.” NCT04801095 ↗ |